Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Chemizon Collaborates with Korean Research Institute

publication date: Feb 13, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Chemizon, a drug discovery CRO based in the US but with labs in Seoul and Beijing, will collaborate with the Korean Research Institute of Bioscience and Biotechnology (KRIBB) to commercialize KRIBB’s IP. To do this, the two entities will spin out a new biotech company. Chemizon said that its new Chemizon-Oakwood Bioventures private equity fund will be the lead investor in the new KRIBB company, currently given the working name “NuCo.” Chemizon-Oakwood Bioventures will build a management team and incubate the company. At the same time, Chemizon will use its integrated drug discovery platform to help convert KRIBB’s discoveries into small molecule therapeutics.

Stock Symbols: (NSDQ: ARRY) (KOSDAQ:010170)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors